Your browser doesn't support javascript.
loading
Retrospective Study on the Features and Outcomes of a Tuscany COVID-19 Hospitalized Patients Cohort: Preliminary Results.
Silvestri, Caterina; Stasi, Cristina; Profili, Francesco; Bartolacci, Simone; Sessa, Emiliano; Tacconi, Danilo; Villari, Liliana; Carrozzi, Laura; Dotta, Francesco; Bargagli, Elena; Donnini, Sandra; Masotti, Luca; Rasero, Laura; Lavorini, Federico; Pistelli, Francesco; Chimera, Davide; Sorano, Alessandra; Pacifici, Martina; Milli, Caterina; Voller, Fabio.
Afiliação
  • Silvestri C; Epidemiology Unit, Regional Health Agency of Tuscany, 50141 Florence, Italy.
  • Stasi C; Epidemiology Unit, Regional Health Agency of Tuscany, 50141 Florence, Italy.
  • Profili F; Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy.
  • Bartolacci S; Epidemiology Unit, Regional Health Agency of Tuscany, 50141 Florence, Italy.
  • Sessa E; Epidemiology Unit, Regional Health Agency of Tuscany, 50141 Florence, Italy.
  • Tacconi D; Epidemiology Unit, Regional Health Agency of Tuscany, 50141 Florence, Italy.
  • Villari L; Infectious Diseases Unit, PO San Donato, 52100 Arezzo, Italy.
  • Carrozzi L; Division of Pneumology, AUSL Toscana Nord-Ovest, Apuane Hospital, 54100 Massa, Italy.
  • Dotta F; Pneumology Unit, Pisa University Hospital, 56124 Pisa, Italy.
  • Bargagli E; Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy.
  • Donnini S; Diabetes and Metabolic Diseases Unit, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy.
  • Masotti L; Respiratory Diseases Unit, Department Medical Sciences, Surgery and Neurological Sciences, Siena University, 53100 Siena, Italy.
  • Rasero L; Department of Life Sciences, University of Siena, 53100 Siena, Italy.
  • Lavorini F; Internal Medicine II and Stroke Unit, San Giuseppe Hospital, 20123 Empoli, Italy.
  • Pistelli F; Department of Health Sciences, Clinical Innovations and Research Unit, Careggi University Hospital, University of Florence, 50121 Florence, Italy.
  • Chimera D; Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy.
  • Sorano A; Pneumology Unit, Pisa University Hospital, 56124 Pisa, Italy.
  • Pacifici M; Pneumology Unit, Pisa University Hospital, 56124 Pisa, Italy.
  • Milli C; Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy.
  • Voller F; Epidemiology Unit, Regional Health Agency of Tuscany, 50141 Florence, Italy.
  • Sprint Study Group; Epidemiology Unit, Regional Health Agency of Tuscany, 50141 Florence, Italy.
J Clin Med ; 13(16)2024 Aug 07.
Article em En | MEDLINE | ID: mdl-39200770
ABSTRACT

Background:

A few months after the COVID-19 pandemic onset, knowledge of SARS-CoV-2 infection and outcomes and treatments blew up. This paper aimed to evaluate the features of a Tuscany COVID-19 hospitalized cohort and to identify risk factors for COVID-19 severity.

Methods:

This retrospective observational COVID-19 cohort study (1 March 2020-1 March 2021) was conducted on patients ≥ 18 years old, admitted to Tuscany Hospital, and subjected to follow-up within 12 months after discharge. Patients were enrolled at Pisana, Senese and Careggi University Hospitals, and South East, North West, and Center Local Hospitals.

Results:

2888 patients (M = 58.5%, mean age = 66.2 years) were enrolled, of whom 14.3% (N = 413) were admitted to an intensive care unit. Smokers were 25%, and overweight and obese 65%. The most used drugs were corticosteroids, antacids, antibiotics, and antithrombotics, all antiviral drugs, with slight differences between 2020 and 2021. A strong association was found between outcomes of evolution towards critical COVID-19 (non-invasive mechanical ventilation (NIV) and/or admission to intensive care) and smoking (RR = 4.91), ex-smoking (RR = 3.48), overweight (RR = 1.30), obese subjects (RR = 1.62), comorbidities (aRR = 1.38). The alteration of liver enzymes (aspartate aminotransferase, alanine aminotransferase, or gamma-glutamyl transpeptidase) was associated with NIV (aOR = 2.28).

Conclusions:

Our cohort, characterized by patients with a mean age of 66.2 years, showed 65% of patients were overweight and obese. Smoking/ex-smoking, overweight/obesity, and other comorbidities were associated with COVID-19 adverse outcomes. The findings also demonstrated that alterations in liver enzymes were associated with worse outcomes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article